Episodes

  • Top Six Trials From AHA 2024: BROAD, SUMMIT, OPTION, CLEAR SYNERGY (Spironolactone and Colchicine), My Heart Your Heart

    Top Six Trials From AHA 2024: BROAD, SUMMIT, OPTION, CLEAR SYNERGY (Spironolactone and Colchicine), My Heart Your Heart
    Nov 21 2024

    In this special edition of Eagle’s Eye View, Dr. Eagle looks at the most important trials presented at the recent AHA scientific sessions: 1) BROAD, exploring more intensive blood pressure control; 2) SUMMIT, evaluating tirzepatide use in obesity-related HFpEF in people with diabetes; 3) OPTION, comparing left atrial appendage closure to oral anticoagulation therapy for stroke protection in post-ablation patients with atrial fibrillation; 4) CLEAR SYNERGY, dual trials on the use of spironolactone vs. placebo and colchicine vs. placebo in patients with myocardial infarction, and 5) Project My Heart Your Heart, developing a protocol of the use of refurbished pacemakers.

    Subscribe to Eagle’s Eye View

    Show more Show less
    13 mins
  • Exercise Training in HCM; Management of Kawasaki Disease; Race, Social Determinants of Health, Polygenic Risk for CHD

    Exercise Training in HCM; Management of Kawasaki Disease; Race, Social Determinants of Health, Polygenic Risk for CHD
    Nov 20 2024

    In this week’s View, Dr. Eagle looks at exercise training in patients with hypertrophic cardiomyopathy (HCM). He then reviews the diagnosis and management of Kawasaki Disease. Finally, Dr. Eagle discusses the association of self-reported race, social determinants of health (SDoH), and polygenic risk for coronary heart disease (CHD).

    Subscribe to Eagle’s Eye View

    Show more Show less
    9 mins
  • Transseptal Mitral Valve-in-Valve Procedure, Complete vs. Culprit-Only Revascularization in Older Patients, Hypertensive Pregnancy and MI Risk

    Transseptal Mitral Valve-in-Valve Procedure, Complete vs. Culprit-Only Revascularization in Older Patients, Hypertensive Pregnancy and MI Risk
    Nov 13 2024
    In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs. culprit-only revascularization in older patients with myocardial infarction (MI) with or without ST-segment elevation. Finally, Dr. Eagle discusses hypertensive disorders of pregnancy and whether they increase the risk for MI. Subscribe to Eagle’s Eye View
    Show more Show less
    8 mins
  • TAVR in Younger Patients; Atorvastatin vs. Rosuvastatin; Sedentary Behavior and Blood Pressure

    TAVR in Younger Patients; Atorvastatin vs. Rosuvastatin; Sedentary Behavior and Blood Pressure
    Nov 6 2024
    In this week’s View, Dr. Eagle looks at the outcomes of balloon-expandable transcatheter aortic valve replacement (TAVR) in younger patients. He then explores the comparative effectiveness and safety of atorvastatin versus rosuvastatin. Finally, Dr. Eagle discusses the results of the RESET-BP randomized trial that studied the effects of sedentary behavior’s reduction of blood pressure in desk workers. Subscribe to Eagle’s Eye View
    Show more Show less
    7 mins
  • Top Four Trials from TCT 2024: EARLY TAVR, TRISCEND II for Tricuspid Regurgitation, ECLIPSE on orbital atherectomy, and CLEAR SYNERGY (OASIS 9) & colchicine treatment

    Top Four Trials from TCT 2024: EARLY TAVR, TRISCEND II for Tricuspid Regurgitation, ECLIPSE on orbital atherectomy, and CLEAR SYNERGY (OASIS 9) & colchicine treatment
    Nov 5 2024

    In this special edition of Eagle’s Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; 2) TRISCEND II looking at the Evoque transcatheter tricuspid valve replacement (TTVR) system for severe tricuspid regurgitation; 3) ECLIPSE evaluating orbital atherectomy prior to drug-eluting stent implant compared to conventional PCI; and 4) CLEAR SYNERGY (OASIS 9) assessing the effects of colchicine after PCI for a STEMI or large NSTEMI.

    Subscribe to Eagle’s Eye View

    Show more Show less
    10 mins
  • Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

    Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses
    Oct 30 2024
    In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension. Subscribe to Eagle’s Eye View
    Show more Show less
    9 mins
  • Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI

    Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI
    Oct 23 2024

    In this week’s View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis.

    Subscribe to Eagle’s Eye View

    Show more Show less
    9 mins
  • Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS

    Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS
    Oct 16 2024
    In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS). Subscribe to Eagle’s Eye View
    Show more Show less
    10 mins